89bio presents updated clinical data from positive phase 1b/2a study of bio89-100 in nash at aasld's the liver meeting® 2020

– data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing –

ETNB Ratings Summary

ETNB Quant Ranking